L-165041 (CAS 79558-09-1)
QUICK LINKS
L-165041 is a cell permeable PPARbeta (peroxisome proliferator-activated receptor beta) agonist which induces adipocyte differentiation in NIH-PPARbeta cells. In addition, this ligand reduces lipid accumulation in the liver and decreases total hepatic cholesterol and triglyceride content. Studies suggest that L-165041 affects mRNA expression by reducing the expression of PPARgamma, apolipoprotein B, interleukin 1 beta (IL-1beta), and interleukin-6, while increasing the expression of PPARbeta, lipoprotein lipase (LPL), and ATP-binding cassette transporter G1 (ABCG1). Furthermore, upon binding to PPARbeta L-165041 suppresses vascular smooth muscle proliferation and migration by inhibiting the cell cycle, specifically blocking G1 to S phase progression and repressing the phosphorylation of retinoblastoma protein (Rb) in rats. Alternate studies suggest that L-165041 suppresses the cytokine-induced expression of VCAM-1 (vascular cell adhesion molecule-1) and increases UCP3 (uncoupling protein 3) gene expression in L6 myotubes. L-165041 is an activator of PPAR beta.
L-165041 (CAS 79558-09-1) References
- Activation of PPARdelta alters lipid metabolism in db/db mice. | Leibowitz, MD., et al. 2000. FEBS Lett. 473: 333-6. PMID: 10818235
- PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. | Rival, Y., et al. 2002. Eur J Pharmacol. 435: 143-51. PMID: 11821020
- Peroxisome proliferator-activated receptor beta/delta activation inhibits hypertrophy in neonatal rat cardiomyocytes. | Planavila, A., et al. 2005. Cardiovasc Res. 65: 832-41. PMID: 15721863
- Effect of PPAR-delta agonist on the expression of visfatin, adiponectin, and resistin in rat adipose tissue and 3T3-L1 adipocytes. | Choi, KC., et al. 2007. Biochem Biophys Res Commun. 357: 62-7. PMID: 17418807
- PPAR delta agonist L-165041 inhibits rat vascular smooth muscle cell proliferation and migration via inhibition of cell cycle. | Lim, HJ., et al. 2009. Atherosclerosis. 202: 446-54. PMID: 18585719
- PPARdelta ligand L-165041 ameliorates Western diet-induced hepatic lipid accumulation and inflammation in LDLR-/- mice. | Lim, HJ., et al. 2009. Eur J Pharmacol. 622: 45-51. PMID: 19766624
- Advanced glycation end products-induced apoptosis attenuated by PPARdelta activation and epigallocatechin gallate through NF-kappaB pathway in human embryonic kidney cells and human mesangial cells. | Liang, YJ., et al. 2010. Diabetes Metab Res Rev. 26: 406-16. PMID: 20583309
- Peroxisome proliferator-activated receptor Δ downregulates the expression of the receptor for advanced glycation end products and pro-inflammatory cytokines in the kidney of streptozotocin-induced diabetic mice. | Liang, YJ., et al. 2011. Eur J Pharm Sci. 43: 65-70. PMID: 21458563
- The PPARΔ ligand L-165041 inhibits VEGF-induced angiogenesis, but the antiangiogenic effect is not related to PPARΔ. | Park, JH., et al. 2012. J Cell Biochem. 113: 1947-54. PMID: 22234939
- L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression. | Liang, YJ., et al. 2013. Eur J Pharmacol. 715: 33-8. PMID: 23831394
- The PPARβ agonist L-165041 promotes VEGF mRNA stabilization in HPV18-harboring HeLa cells through a receptor-independent mechanism. | Roche, E., et al. 2014. Cell Signal. 26: 433-43. PMID: 24172859
- Glucagon-like peptide receptor agonists attenuate advanced glycation end products-induced inflammation in rat mesangial cells. | Chang, JT., et al. 2017. BMC Pharmacol Toxicol. 18: 67. PMID: 29065926
- Peroxisome proliferator-activated receptor delta-PPARδ agonist (L-165041) enhances bovine embryo survival and post vitrification viability. | Sánchez Viafara, JA., et al. 2022. Reprod Fertil Dev. 34: 658-668. PMID: 35468312
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
L-165041, 5 mg | sc-203094 | 5 mg | $153.00 |